Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial

Marie Véron, Sylvie Chevret, Jean‐Jacques Grob, M. Beylot‐Barry, Philippe Saïag, Aude Fléchon, Benoît You, E. Maubec, Thomas Jouary, Elise Toulemonde, Philippe Jamme, Laëtitia Gambotti, Assia Lamrani-Ghaouti, A. Dupuy, Célèste Lebbé, N. Basset Seguin, Nadine Houédé, M.‐T. Leccia, Fanny Le Du, Michel De Pontville, Caroline Gaudy‐Marquestre, B. Guillot, Clotilde Simon, Aurélien Marabelle, Laurent Mortier